nasonex 50 mikrogramov/vpih pršilo za nos, suspenzija
merck sharp & dohme, d.o.o. - mometazonfuroat - pršilo za nos, suspenzija - mometazonfuroat 50 µg / 1 vpih - mometazon
nasonex 50 mikrogramov/vpih pršilo za nos, suspenzija
merck sharp & dohme, d.o.o. - mometazonfuroat - pršilo za nos, suspenzija - mometazonfuroat 50 µg / 1 vpih - mometazon
vasotec 10 mg tablete
merck sharp & dohme, d.o.o. - enalaprilijev maleat - tableta - enalaprilijev maleat 10 mg / 1 tableta - enalapril
vasotec 20 mg tablete
merck sharp & dohme, d.o.o. - enalaprilijev maleat - tableta - enalaprilijev maleat 20 mg / 1 tableta - enalapril
vasotec 5 mg tablete
merck sharp & dohme, d.o.o. - enalaprilijev maleat - tableta - enalaprilijev maleat 5 mg / 1 tableta - enalapril
natabec
kapsula
natabec f
kapsula
zostavax
merck sharp & dohme b.v. - virus varicella-zoster (v živo, oslabljen) - herpes zoster; immunization - virusna cepiva - zdravilo zostavax je indicirano za preprečevanje herpes zoster ("zoster" ali pasovec) in posterpetične nevralgije povezane s herpes-zosterom. zostavax je označen za imunizacijo posameznikov 50 let ali starejši.
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - cepiva - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. uporaba shingrix mora biti v skladu z uradnimi priporočili.
sarclisa
sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.